Company · Private

Life Biosciences

Advancing partial reprogramming toward the clinic with an initial focus on optic neuropathy.

Listing

Private

Ticker

—

Headquarters

Boston, US

Founded

2017

Technology

Partial epigenetic reprogramming (OSK)

Longevity thesis

Starting in the eye contains delivery and safety risk while still testing the core rejuvenation hypothesis in humans.

Programmes

ER-100IND-enabling
NAION / glaucoma

Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.